Showing results (61-70 of 76) with videos related to
Sort By:
Pageof 8
Journal of Medical Screening|October 18, 2008
Early reporting for cancer screening trialsStuart G Baker, Barnett S Kramer, Philip C ProrokThe International Journal of Biostatistics|April 14, 2012
Evaluating a new marker for risk prediction using the test tradeoff: an updateStuart G Baker, Ben Van Calster, Ewout W SteyerbergBiometrics|August 16, 2011
Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific timeStuart G Baker, Daniel J Sargent, Marc Buyse, et al.Journal of Clinical Epidemiology|September 2, 2024
Surrogate endpoint metaregression: useful statistics for regulators and trialistsStuart G Baker, Marissa N D Lassere, Wang Pok LoDiscovery Medicine|April 3, 2012
Biomarkers, subgroup evaluation, and clinical trial designStuart G Baker, Barnett S Kramer, Daniel J Sargent, et al.Journal of the Royal Statistical Society. Series A, (Statistics in Society)|January 14, 2010
Using relative utility curves to evaluate risk predictionStuart G Baker, Nancy R Cook, Andrew Vickers, et al.BMC Medical Research Methodology|April 12, 2003
Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screeningStuart G Baker, Diane Erwin, Barnett S Kramer, et al.Biostatistics (Oxford, England)|June 1, 2005
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariatesStuart G Baker, Garrett M Fitzmaurice, Laurence S Freedman, et al.Biostatistics (Oxford, England)|February 23, 2010
Transparency and reproducibility in data analysis: the Prostate Cancer Prevention TrialStuart G Baker, Amy K Darke, Paul Pinsky, et al.Clinical Trials (London, England)|March 17, 2006
Evaluating markers for the early detection of cancer: overview of study designs and methodsStuart G Baker, Barnett S Kramer, Martin McIntosh, et al.Pageof 8